Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Alamar Biosciences (ALMR) 10K Form and Latest SEC Filings 2026

$20.51 -0.35 (-1.68%)
As of 04:00 PM Eastern

Latest Alamar Biosciences SEC Filings & Recent Activity

Alamar Biosciences (NASDAQ:ALMR) has submitted 35+ documents to the U.S. Securities and Exchange Commission (SEC) since 2026. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-Q submitted on May 8, 2026.

Form 4
Alamar Biosciences, Inc. Reports Ownership Change on Apr. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Alamar Biosciences Files Current Report on May. 8, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Alamar Biosciences Files Quarterly Report on May. 8, 2026

The 10-Q contains Alamar Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Alamar Biosciences SEC Filing History

Browse Alamar Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/08/2026 7:30 AM
Alamar Biosciences (2104204) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/08/2026 7:05 AM
Alamar Biosciences (2104204) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2026 3:24 PM
Alamar Biosciences (2104204) Subject
Illumina Innovation Fund II, L.P. (1779218) Filed by
Form SCHEDULE 13D
04/23/2026 12:57 PM
Alamar Biosciences (2104204) Subject
Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Filed by
Form SCHEDULE 13D
04/22/2026 3:16 PM
Alamar Biosciences (2104204) Issuer
Qiming Corporate GP VI, Ltd. (2059127) Reporting
Qiming GP VIII, LLC (2129740) Reporting
Qiming GP VIII-HC, LLC (2129671) Reporting
Qiming Managing Directors Fund VI, L.P. (1733282) Reporting
Qiming Venture Partners VI, L.P. (1733278) Reporting
Qiming Venture Partners VIII Investments, LLC (2129618) Reporting
Qiming Venture Partners VIII-HC, L.P. (1910025) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 11:15 PM
Alamar Biosciences (2104204) Filer
Form EFFECT
04/20/2026 7:37 PM
Alamar Biosciences (2104204) Issuer
Chambers Rebecca (1823563) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:45 PM
Alamar Biosciences (2104204) Issuer
Illumina Innovation Fund II GP, L.L.C. (1779219) Reporting
Illumina Innovation Fund II, L.P. (1779218) Reporting
Illumina Innovation Fund III GP, L.L.C. (2032563) Reporting
Illumina Innovation Fund III, L.P. (2032562) Reporting
Naclerio Nicholas (1534166) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:31 PM
Alamar Biosciences (2104204) Issuer
Naclerio Nicholas (1534166) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:33 PM
Alamar Biosciences (2104204) Issuer
McAnear Justin J. (1786386) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:33 PM
Alamar Biosciences (2104204) Issuer
Luo Yuling (2126941) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:34 PM
Alamar Biosciences (2104204) Issuer
Chen Shiping (2126944) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:35 PM
Alamar Biosciences (2104204) Issuer
White Timothy Ogden (2126704) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 7:37 PM
Alamar Biosciences (2104204) Issuer
Witney Frank (1455312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 3:40 PM
Alamar Biosciences (2104204) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/20/2026 3:02 PM
Alamar Biosciences (2104204) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2026 7:39 AM
Alamar Biosciences (2104204) Filer
Form POS AM
04/17/2026 3:34 PM
Alamar Biosciences (2104204) Filer
Form 424B4
04/16/2026 11:15 PM
Alamar Biosciences (2104204) Filer
Form EFFECT
04/16/2026 8:23 PM
Alamar Biosciences (2104204) Issuer
Witney Frank (1455312) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:23 PM
Alamar Biosciences (2104204) Issuer
Qiming Corporate GP VI, Ltd. (2059127) Reporting
Qiming GP VIII, LLC (2129740) Reporting
Qiming GP VIII-HC, LLC (2129671) Reporting
Qiming Managing Directors Fund VI, L.P. (1733282) Reporting
Qiming Venture Partners VI, L.P. (1733278) Reporting
Qiming Venture Partners VIII Investments, LLC (2129618) Reporting
Qiming Venture Partners VIII-HC, L.P. (1910025) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:30 PM
Alamar Biosciences (2104204) Issuer
Illumina Innovation Fund II GP, L.L.C. (1779219) Reporting
Illumina Innovation Fund II, L.P. (1779218) Reporting
Illumina Innovation Fund III GP, L.L.C. (2032563) Reporting
Illumina Innovation Fund III, L.P. (2032562) Reporting
Naclerio Nicholas (1534166) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:09 PM
Alamar Biosciences (2104204) Issuer
Luo Yuling (2126941) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:13 PM
Alamar Biosciences (2104204) Issuer
Chen Shiping (2126944) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:14 PM
Alamar Biosciences (2104204) Issuer
White Timothy Ogden (2126704) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:16 PM
Alamar Biosciences (2104204) Issuer
McAnear Justin J. (1786386) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:17 PM
Alamar Biosciences (2104204) Issuer
Naclerio Nicholas (1534166) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:19 PM
Alamar Biosciences (2104204) Issuer
Chambers Rebecca (1823563) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 8:21 PM
Alamar Biosciences (2104204) Issuer
Ratcliffe Ian W (1304782) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 7:33 PM
Alamar Biosciences (2104204) Filer
Form S-1MEF
04/16/2026 2:14 PM
Alamar Biosciences (2104204) Filer
Form CERT
04/16/2026 8:25 AM
Alamar Biosciences (2104204) Filer
Form S-1/A
04/15/2026 3:05 PM
Alamar Biosciences (2104204) Filer
Form 8-A12B
04/13/2026 5:05 AM
Alamar Biosciences (2104204) Filer
Form S-1/A
03/27/2026 3:12 PM
Alamar Biosciences (2104204) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Alamar Biosciences SEC Filings - Frequently Asked Questions

Alamar Biosciences (ALMR) has submitted 35+ filings to the SEC since 2026. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 10-Q submitted on May 8, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ALMR) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners